ReviewHematology. American Society of Hematology. Education Program2020
How do I sequence therapy for follicular lymphoma?
Review in Hematology. American Society of Hematology. Education Program, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.Haematologica · 2024Trial
- Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study.Blood advances · 2026Article
- A Phase II Study ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy.Blood cancer journal · 2026Article
- Review
- Matching plus regression adjustment for the estimation of the average treatment effect on survival outcomes: a case study with mosunetuzumab in relapsed/refractory follicular lymphoma.BMC medical research methodology · 2025Article
- Safety in Subsequent Lines of Therapy in Patients With Relapsed/Refractory Follicular Lymphoma.Journal of the advanced practitioner in oncology · 2024Review
- Article
- Functional precision oncology for follicular lymphoma with patient-derived xenograft in avian embryos.Leukemia · 2024Article
- Review
- Treatment selection for patients with relapsed or refractory follicular lymphoma.Frontiers in oncology · 2023Article
- Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.Blood reviews · 2022Review
- SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab.Blood advances · 2022Article
- Prospects in the management of patients with follicular lymphoma beyond first-line therapy.Haematologica · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
In the past decade, many new agents have been introduced for the management of follicular lymphoma, and therapeutic strategies have evolved over time. The clinical benefits of the different treatments vary and, at the time of progression, are influenced by patient and disease characteristics, the duration of the interval from last treatment, and the nature of the treatments previously administered. Altogether, this results in a marked heterogeneity of clinical situations encountered during the treatment of these patients. Despite numerous trials performed in the field, there is no single standard of care for patients undergoing second-line treatment or beyond. Furthermore, patients recruited in these studies have characteristics that rarely represent the full spectrum of possible clinical presentations. Therefore, to optimally individualize treatment, all of the risks (short- and long-term) and benefits of the available options should be well known. Discussing the goals of therapy with the patient at each intervention is also critical in providing an optimal sequence of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.